View Past PerformanceAspen Pharmacare Holdings バランスシートの健全性財務の健全性 基準チェック /66Aspen Pharmacare Holdingsの総株主資本はZAR81.1B 、総負債はZAR32.9Bで、負債比率は40.6%となります。総資産と総負債はそれぞれZAR128.0BとZAR47.0Bです。 Aspen Pharmacare Holdingsの EBIT はZAR6.0Bで、利息カバレッジ比率4.1です。現金および短期投資はZAR5.6Bです。主要情報40.63%負債資本比率R32.94b負債インタレスト・カバレッジ・レシオ4.1x現金R5.62bエクイティR81.09b負債合計R46.96b総資産R128.05b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 09Aspen Pharmacare Holdings Limited to Report Fiscal Year 2026 Results on Sep 02, 2026Aspen Pharmacare Holdings Limited announced that they will report fiscal year 2026 results on Sep 02, 2026お知らせ • Feb 06Aspen Pharmacare Holdings Limited to Report Q2, 2026 Results on Mar 03, 2026Aspen Pharmacare Holdings Limited announced that they will report Q2, 2026 results at 1:00 PM, South Africa Standard Time on Mar 03, 2026お知らせ • Dec 04Aspen Pharmacare Holdings Limited Approves Election of Social & Ethics Committee MembersASPEN Pharmaceutical Holdings Limited announced that at its AGM held on 4 December 2025, the shareholders approved the Election of Yvonne Muthien as a member of the Social & Ethics committee, Election of Kuseni Dlamini as a member of the Social & Ethics committee, Election of Ben Kruger as a member of the Social & Ethics committee, Election of Reginald Haman as a member of the Social & Ethics committee.お知らせ • Oct 13Aspen Secures SAHPRA Approval for Mounjaro as Chronic Weight Management TreatmentAspen announced the South African Health Products Regulatory Authority ("SAHPRA") has approved a new indication for the once-weekly prescription only treatment, Mounjaro® (tirzepatide), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, effective October 2025i. Aspen launched Lilly's Mounjaro® (tirzepatide) the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in December 2024 for the treatment of Type 2 diabetes in South Africa.お知らせ • Oct 02Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 04, 2025Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 04, 2025. Location: aspen`s head office, aspen place, 9 rydall vale park, douglas saunders drive, la lucia ridge, durban South Africaお知らせ • Sep 04Aspen Pharmacare Holdings Limited announces Annual dividend, payable on October 06, 2025Aspen Pharmacare Holdings Limited announced Annual dividend of ZAR 2.1100 per share payable on October 06, 2025, ex-date on October 01, 2025 and record date on October 03, 2025.お知らせ • Jan 11+ 1 more updateAspen Pharmacare Holdings Limited to Report Fiscal Year 2025 Results on Sep 03, 2025Aspen Pharmacare Holdings Limited announced that they will report fiscal year 2025 results on Sep 03, 2025お知らせ • Sep 04Aspen Pharmacare Holdings Limited Declares Gross Dividend, Payable on 23 September 2024The Board of Aspen Pharmacare Holdings Limited has declared a gross dividend of 359 cents per ordinary share (2023: 342 cents per share) (or 287.2 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies) which represents an increase of 5% in gross dividend per share and will be paid from income reserves. Last day to trade cum dividend is 17 September 2024. Shares commence trading ex-dividend is 18 September 2024. Record date is 20 September 2024. Payment date is 23 September 2024.お知らせ • Mar 21+ 1 more updateAspen Pharmacare Holdings Limited, Annual General Meeting, Dec 05, 2024Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 05, 2024.お知らせ • Jan 18Aspen Pharmacare Holdings Limited to Report First Half, 2024 Results on Mar 04, 2024Aspen Pharmacare Holdings Limited announced that they will report first half, 2024 results on Mar 04, 2024お知らせ • Dec 08Aspen Pharmacare Holdings Limited Announces Changes to its BoardAspen Pharmacare Holdings Limited announced that Ms. Raeesa Khan has been appointed by the Board as Group Company Secretary of the company with effect from 1 January 2024. Ms. Khan has been with Aspen since 2016 and prior to her appointment served as the Group Legal Counsel Lead: Commercial and Corporate. She is an admitted attorney of the High Court of South Africa and has been in practice and in corporate roles for more than 10 years. She also has prior experience in both corporate legal and administration as well as company secretarial services. Mr. Reginald Haman, Group Chief Corporate Services Officer, who was appointed in March 2023 as Company Secretary to ensure a smooth transition after the tragic passing of the previous Company Secretary, Riaan Verster, will accordingly step down as Company Secretary on 31 December 2023.お知らせ • Aug 31Aspen Pharmacare Holdings Limited Declares Gross Dividend, Payable on 26 September 2023Aspen Pharmacare Holdings Limited declared a gross dividend of 342 cents per ordinary share (2022: 326 cents per share) (or 273,6 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies)which represents an increase of 5% in gross dividend per share. Shareholders should seek their own advice on the tax consequences associated with the dividend and are particularly encouraged to ensure their records are up to date with Aspen so that the correct withholding tax is applied to their dividend. The Company income tax number is 9325178714. The issued share capital of the Company is 446,252,332 ordinary shares. Last day to trade cum dividend: 19 September 2023, Shares commence trading ex-dividend: 20 September 2023, Record date: 22 September 2023 and Payment date: 26 September 2023. Share certificates may not be dematerialized or rematerialized between 20 September 2023 and 22 September 2023.お知らせ • Jun 18Aspen Pharmacare Holdings Limited Announces Changes to the Board CommitteesAspen Pharmacare Holdings Limited announced the Following the resignation of Ms Babalwa Ngonyama as a director of the Board, the Board hereby announces the below changes to its committees: Audit & Risk Committee: Appointment of Mr. B J Kruger as the chairperson, Appointment of Ms. Y G Muthien as a member; Social & Ethics Committee: Stepping down of Mr. B J Kruger as the chairperson, and remaining a member of the committee, Appointment of Ms Y G Muthien as the chairperson. Further announcements will be made in respect of the appointment of an additional director to the Board to strengthen the Audit & Risk Committee and to ensure that Aspen meets its diversity requirements.お知らせ • Jan 31Aspen Pharmacare Holdings Limited Announces Demise of Riaan Verster, Company SecretaryAspen Pharmacare Holdings Limited announced the passing of its company secretary, Riaan Verster, on 28 January 2023, following a motorcycle accident. Riaan was appointed as the company secretary of Aspen on 1 November 2011.お知らせ • Jan 10+ 2 more updatesAspen Pharmacare Holdings Limited to Report Fiscal Year 2023 Results on Aug 30, 2023Aspen Pharmacare Holdings Limited announced that they will report fiscal year 2023 results on Aug 30, 2023財務状況分析短期負債: LDZUの 短期資産 ( ZAR57.3B ) が 短期負債 ( ZAR15.8B ) を超えています。長期負債: LDZUの短期資産 ( ZAR57.3B ) が 長期負債 ( ZAR31.2B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: LDZUの 純負債対資本比率 ( 33.7% ) は 満足できる 水準であると考えられます。負債の削減: LDZUの負債対資本比率は、過去 5 年間で56.5%から40.6%に減少しました。債務返済能力: LDZUの負債は 営業キャッシュフロー によって 十分にカバー されています ( 21% )。インタレストカバレッジ: LDZUの負債に対する 利息支払い は EBIT ( 4.1 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/08 08:30終値2026/06/08 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aspen Pharmacare Holdings Limited 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Rendani MagalelaAbsa Bank LimitedAndre BekkerArqaam Capital Research Offshore S.A.L.Boitshepo SeruweAvior Capital Markets11 その他のアナリストを表示
お知らせ • Mar 09Aspen Pharmacare Holdings Limited to Report Fiscal Year 2026 Results on Sep 02, 2026Aspen Pharmacare Holdings Limited announced that they will report fiscal year 2026 results on Sep 02, 2026
お知らせ • Feb 06Aspen Pharmacare Holdings Limited to Report Q2, 2026 Results on Mar 03, 2026Aspen Pharmacare Holdings Limited announced that they will report Q2, 2026 results at 1:00 PM, South Africa Standard Time on Mar 03, 2026
お知らせ • Dec 04Aspen Pharmacare Holdings Limited Approves Election of Social & Ethics Committee MembersASPEN Pharmaceutical Holdings Limited announced that at its AGM held on 4 December 2025, the shareholders approved the Election of Yvonne Muthien as a member of the Social & Ethics committee, Election of Kuseni Dlamini as a member of the Social & Ethics committee, Election of Ben Kruger as a member of the Social & Ethics committee, Election of Reginald Haman as a member of the Social & Ethics committee.
お知らせ • Oct 13Aspen Secures SAHPRA Approval for Mounjaro as Chronic Weight Management TreatmentAspen announced the South African Health Products Regulatory Authority ("SAHPRA") has approved a new indication for the once-weekly prescription only treatment, Mounjaro® (tirzepatide), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management, effective October 2025i. Aspen launched Lilly's Mounjaro® (tirzepatide) the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in December 2024 for the treatment of Type 2 diabetes in South Africa.
お知らせ • Oct 02Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 04, 2025Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 04, 2025. Location: aspen`s head office, aspen place, 9 rydall vale park, douglas saunders drive, la lucia ridge, durban South Africa
お知らせ • Sep 04Aspen Pharmacare Holdings Limited announces Annual dividend, payable on October 06, 2025Aspen Pharmacare Holdings Limited announced Annual dividend of ZAR 2.1100 per share payable on October 06, 2025, ex-date on October 01, 2025 and record date on October 03, 2025.
お知らせ • Jan 11+ 1 more updateAspen Pharmacare Holdings Limited to Report Fiscal Year 2025 Results on Sep 03, 2025Aspen Pharmacare Holdings Limited announced that they will report fiscal year 2025 results on Sep 03, 2025
お知らせ • Sep 04Aspen Pharmacare Holdings Limited Declares Gross Dividend, Payable on 23 September 2024The Board of Aspen Pharmacare Holdings Limited has declared a gross dividend of 359 cents per ordinary share (2023: 342 cents per share) (or 287.2 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies) which represents an increase of 5% in gross dividend per share and will be paid from income reserves. Last day to trade cum dividend is 17 September 2024. Shares commence trading ex-dividend is 18 September 2024. Record date is 20 September 2024. Payment date is 23 September 2024.
お知らせ • Mar 21+ 1 more updateAspen Pharmacare Holdings Limited, Annual General Meeting, Dec 05, 2024Aspen Pharmacare Holdings Limited, Annual General Meeting, Dec 05, 2024.
お知らせ • Jan 18Aspen Pharmacare Holdings Limited to Report First Half, 2024 Results on Mar 04, 2024Aspen Pharmacare Holdings Limited announced that they will report first half, 2024 results on Mar 04, 2024
お知らせ • Dec 08Aspen Pharmacare Holdings Limited Announces Changes to its BoardAspen Pharmacare Holdings Limited announced that Ms. Raeesa Khan has been appointed by the Board as Group Company Secretary of the company with effect from 1 January 2024. Ms. Khan has been with Aspen since 2016 and prior to her appointment served as the Group Legal Counsel Lead: Commercial and Corporate. She is an admitted attorney of the High Court of South Africa and has been in practice and in corporate roles for more than 10 years. She also has prior experience in both corporate legal and administration as well as company secretarial services. Mr. Reginald Haman, Group Chief Corporate Services Officer, who was appointed in March 2023 as Company Secretary to ensure a smooth transition after the tragic passing of the previous Company Secretary, Riaan Verster, will accordingly step down as Company Secretary on 31 December 2023.
お知らせ • Aug 31Aspen Pharmacare Holdings Limited Declares Gross Dividend, Payable on 26 September 2023Aspen Pharmacare Holdings Limited declared a gross dividend of 342 cents per ordinary share (2022: 326 cents per share) (or 273,6 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies)which represents an increase of 5% in gross dividend per share. Shareholders should seek their own advice on the tax consequences associated with the dividend and are particularly encouraged to ensure their records are up to date with Aspen so that the correct withholding tax is applied to their dividend. The Company income tax number is 9325178714. The issued share capital of the Company is 446,252,332 ordinary shares. Last day to trade cum dividend: 19 September 2023, Shares commence trading ex-dividend: 20 September 2023, Record date: 22 September 2023 and Payment date: 26 September 2023. Share certificates may not be dematerialized or rematerialized between 20 September 2023 and 22 September 2023.
お知らせ • Jun 18Aspen Pharmacare Holdings Limited Announces Changes to the Board CommitteesAspen Pharmacare Holdings Limited announced the Following the resignation of Ms Babalwa Ngonyama as a director of the Board, the Board hereby announces the below changes to its committees: Audit & Risk Committee: Appointment of Mr. B J Kruger as the chairperson, Appointment of Ms. Y G Muthien as a member; Social & Ethics Committee: Stepping down of Mr. B J Kruger as the chairperson, and remaining a member of the committee, Appointment of Ms Y G Muthien as the chairperson. Further announcements will be made in respect of the appointment of an additional director to the Board to strengthen the Audit & Risk Committee and to ensure that Aspen meets its diversity requirements.
お知らせ • Jan 31Aspen Pharmacare Holdings Limited Announces Demise of Riaan Verster, Company SecretaryAspen Pharmacare Holdings Limited announced the passing of its company secretary, Riaan Verster, on 28 January 2023, following a motorcycle accident. Riaan was appointed as the company secretary of Aspen on 1 November 2011.
お知らせ • Jan 10+ 2 more updatesAspen Pharmacare Holdings Limited to Report Fiscal Year 2023 Results on Aug 30, 2023Aspen Pharmacare Holdings Limited announced that they will report fiscal year 2023 results on Aug 30, 2023